City-based Elder Pharmaceuticals has strengthened its presence in the Rs 750 crore infection control segment by tying up with Chemische Fabrik Dr Weigert GmbH, German equipment, services and Technology Company.
Elder has introduced Dr Weigert’s advanced infection control products in India to the medical, veterinary, environmental and government sectors. Some of existing products of Elder in the segment are sterisol soap, sterisol hand disinfectant, neodisher range for instruments and devices.
Post the tie-up, Elder’s product portfolio in the segment consists of a complete range of hand hygiene products, disinfects and sterilisation equipment. It has another tie-up in the segment with Sterisol AB of Sweden.
Alok Saxena, director of Elder Pharmaceuticals said, “We are confident that our expertise in handling innovative products, as well as our extensive distribution network covering the entire country, will be the key success factors in India. The infection control segment is growing at 18% per annum which is higher than the total pharmaceutical market’s growth rate of 8.6%.”
Nosocomial infections or hospital acquired infections (HAI) affect approximately 2 million patients or 10% of those hospitalised annually in India. Nearly one-third of nosocomial infections are estimated to be prevented by a property implemented infection control programme. But only less than 10% are actually prevented. HAI has a significant impact on medical costs, hospital stay, and mortality among patients.
“We are upbeat about the sector as we expect awareness and demand to surge in the coming years in view of the growth in the number of private hospitals which are more stringent about hygiene. The rise in medical tourism is also necessitating better hygiene,” Mr Saxena said.